info@reumatika.pl
al. Wilanowska 333, Warszawa
Poniedziałek - Piątek: 8:00 - 20:00
Wyślij dokumenty
+22 100 39 22
+48 538 103 922

Dr n. med.

Janusz Jaworski

specjalista reumatolog

Publikacje naukowe

  1. Efficacy and safety of CT-P47 versus reference tocilizumab: 32-week results of a randomised, active-controlled, double-blind, phase III study in patients with rheumatoid arthritis, including 8 weeks of switching data from reference tocilizumab to CT-P47

    Josef S Smolen, Jakub Trefler, Artur Racewicz, Janusz Jaworski, Agnieszka Zielińska, Marek Krogulec, Sławomir Jeka, Rafał Wojciechowski, Katarzyna Kolossa, Anna Dudek, Magdalena Krajewska-Włodarczyk, Paweł Hrycaj, Piotr Adrian Klimiuk, Gerd R Burmester, SungHyun Kim, YunJu Bae, GoEun Yang, YooBin Jung, JiWoo Hong, Edward Keystone BMJ Journals, 2024.

  2. Efficacy, pharmacokinetics and safety of subcutaneous versus intravenous CT-P13 in rheumatoid arthritis: a randomized phase I/III trial.

    Rene Westhovens, Piotr Wiland, Marek Zawadzki, Delina Ivanova, Alfredo Berrocal Kasay, Elias Chalouhi El-Khouri, Éva Balázs, Sergii Shevchuk, Larisa Eliseeva, Mykola Stanislavchuk, Roman Yatsyshyn, Paweł Hrycaj, Janusz Jaworski, Vyacheslav Zhdan, Jakub Trefler, Pavel Shesternya, Sang Joon Lee, Sung Hyun Kim, Jee Hye Suh, Seul Gi Lee, Noo Ri Han, Dae Hyun Yoo. Rheumatology, 2020.

  3. A Novel Formulation Of Ct-P13 (INFLIXIMAB Biosimilar) For Subcutaneous Administration: 1-Year Results From A Part 1 Of Phase I/Iii Randomized Controlled Trial In Patients With Active Rheumatoid Arthritis.

    DaeHyun Yoo, Janusz Jaworski, Ewa Matyska-Piekarska, Svitlana Smiyan, Delina Ivanova, Agnieszka Zielinska, Eve-Kai Raussi, Anastas Batalov, Sangjoon Lee, Jeehye Suh, Noori Han, Rene Westhovens. Poster na konferencji EULAR, Madryt 2019.

  4. Long-Term Efficacy and Safety of Biosimilar CT-P10 Versus Innovator Rituximab in Rheumatoid Arthritis: 48-Week Results from a Randomized Phase III Trial.

    Chang-Hee Suh, Dae Hyun Yoo, Alfredo Berrocal Kasay, Elia Chalouhi El-Khouri, Francisco Fidenci Cons Molina, Pavel Shesternya, Pedro Miranda, Francisco G. Medina-Rodriguez, Piotr Wiland, Sławomir Jeka, Jose Chavez-Corrales, Thomas Linde, Paweł Hrycaj, Mauricio Abello-Banfi, Ihor Hospodarsky, Janusz Jaworski, Mariusz Piotrowski, Marek Brzosko, Marek Krogulec, Sergii Shevchuk, Armando Calvo, Daina Andersone, Won Park, Seung Cheol Shim, Sang Joon Lee, Sung Young Lee. BioDrugs, 2019.

  5. Comparable long-term efficacy, as assessedby patient-reported outcomes, safety andpharmacokinetics, of CT-P13 and reference infliximab in patients with ankylosingspondylitis: 54-week results from therandomized, parallel-group PLANETAS study.

    Won Park, Dae Hyun Yoo, Janusz Jaworski, Jan Brzezicki, Andriy Gnylorybov, Vladimir Kadinov, Irmgadt Goecke Sariego, Carlos Abud-Mendoza, William Jose Otero Escalante, Seong Wook Kang, Daina Andersone, Francisco Blanco, Seung Suh Hong, Sun Hee Lee, Jürgen Braun. Arthritis Research & Therapy, 2018.

  6. Novel Formulation of CT-P13 for Subcutaneous Administration in Patients with Rheumatoid Arthritis: Initial Results from a Phase I/III Randomised Controlled Trial.

    R. Westhovens, D.H. Yoo, J. Jaworski, E. Matyska-Piekarska, S. Smiyan, D. Ivanova, A. Zielinska, E.-K. Raussi, A. Batalov, S.J. Lee, S.Y. Lee, J.H. Suh. Poster na konferencji Eular, Amsterdam, 2018.

  7. Switching From Reference Adalimumab to SB5 (Adalimumab Biosimilar) in Patients With Rheumatoid Arthritis: 52-Week Phase 3 Randomized Study Results.

    Arthritis & Rheumatology, 2018.

  8. Phase 3 Randomized Study of SB5, an Adalimumab Biosimilar, Versus Reference Adalimumab in Patients With Moderate to Severe Rheumatoid Arthritis.

    Michael E. Weinblatt, Asta Baranauskaite, Jaroslaw Niebrzydowski, Eva Dokoupilova, Agnieszka Zielinska, Janusz Jaworski, Artur Racewicz, Margarita Pileckyte, Krystyna Jedrychowicz-Rosiak, Soo Yeon Cheong i Jeehoon Ghil. Arthritis & Rheumatology, 2017.

  9. Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis and current skin involvement: a phase III, randomised, controlled trial (PALACE 3).

    Christopher J Edwards, Francisco J Blanco, Jeffrey Crowley, Charles A Birbara, Janusz Jaworski, Jacob Aelion, Randall M Stevens, Adele Vessey, Xiaojiang Zhan, Paul Bird. Ann Rheum Dis 2016; 75:1065-1073 doi:10.1136/annrheumdis-2015-207963.

  10. Comparable long-term efficacy, as assessed by patient-reported outcomes, safety and pharmacokinetics, of CT-P13 and reference infliximab in patients with ankylosing spondylitis: 54-week results from the randomized, parallel-group PLANETAS study.

    Won Park, Dae Hyun Yoo, corresponding author Janusz Jaworski, Jan Brzezicki, Andriy Gnylorybov, Vladimir Kadinov, Irmgadt Goecke Sariego, Carlos Abud-Mendoza, William Jose Otero Escalante, Seong Wook Kang, Daina Andersone, Francisco Blanco, Seung Suh Hong, Sun Hee Lee and Jürgen Braun. BioMed Central, doi: 10.1186/s13075-016-0930-4, 2016.

  11. Efficacy and safety of CT-P13 (biosimilar infliximab) in patients with rheumatoid arthritis: comparison between switching from reference infliximab to CT-P13 and continuing CT-P13 in the PLANETRA extension study.

    Dae Hyun Yoo, Nenad Prodanovic, Janusz Jaworski, Pedro Miranda, Edgar Ramiterre, Allan Lanzon, Asta Baranauskaite, Piotr Wiland, Carlos Abud-Mendoza, Boycho Oparanov, Svitlana Smiyan, HoUng Kim, Sang Joon Lee, SuYeon Kim, Won Park. (Ann Rheum Dis. 2016 Apr 29. pii: annrheumdis-2015-208786. doi: 10.1136/annrheumdis-2015-208786).

  12. A Phase III, Randomized, Double-Blind Clinical Study Comparing SB5, an Adalimumab Biosimilar, with Adalimumab Reference Product (Humira®) in Patients with Moderate to Severe Rheumatoid Arthritis Despite Methotrexate Therapy (24-week Results).

    Michael E. Weinblatt, Asta Baranauskaite, Jaroslaw Niebrzydowski, Eva Dokoupilova, Agnieszka Zielinska, Karina Sitek-Ziolkowska, Janusz Jaworski, Artur Racewicz, Margarita Pileckyte, Krystyna Jedrychowicz-Rosiak, Vyacheslav Zhdan, Soo Yeon Cheong and Jeehoon Ghil. ACR Late-breaking Abstract Session, 2015.

  13. Efficacy and Safety of CT-P13 (Infliximab biosimilar) over Two Years in Patients with Rheumatoid Arthritis: Comparison Between Continued CT-P13 and Switching from Infliximab to CT-P13.

    Dae Hyun Yoo, Nenad Prodanovic, Janusz Jaworski, Pedro Miranda, Edgar Ramiterre, Allan Lanzon, Asta Baranauskaite, Piotr Wiland, Carlos Abud-Mendoza, Boycho Oparanov, Svitlana Smiyan, YoungKi Son, Won Park, Ulf Müller-Ladner. 2013 ACR/ARHP Annual Meeting, Session Title: ACR Late-Breaking.

  14. Demodex mite infestation in patients with and without rheumatoid arthritis.

    Aleksandra Garbacewicz, Janusz Jaworski and Barbara Grytner-Zięcina. (Acta Parasitologica, 2012, 57(1), 99–100; ISSN 1230-2821).

  15. Decreased expresion of Integrins by Hematopoietic Cells In Patients With Rheumatoid Arthritis and Anemia: Relationship With Bone Marrow Cytokine Levels.

    J. Jaworski, W Maslinski, J. Pazdur, P Sliwinska –Stanczyk, E Kamińska–Tchorzewska, L. Jung, JK. Łącki. J Investig Allergol Clin Immunol., 2008; 18(1):17-21.

  16. Opis przypadku: Czerniak złośliwy u chorej na reumatoidalne zapalenie stawów leczonej infliksymabem.

    Janusz Jaworski, Paula Śliwińska-Stańczyk, Jan Krzysztof Łącki. Reumatologia, 2009; 47, 2: 98–100.

  17. Coincidence of rheumatoid arthritis and acute intermittent porphyria – not an ordinary problem. A case report.

    Maria Maślińska, Janusz Jaworski, Jan K. Łącki. Reumatologia, 2008; 46, 1: 37–38.

  18. Journal Investigating Allergology and Clinical Immunology.

    2008; vol 18(1):17-21.

  19. Dynamika poziomów przeciwciał anty–CCP oraz COMP u pacjentów z reumatoidalnym zapaleniem stawów leczonych leflunomidem.

    J. Ząbek, M. Rell-Bakalarska, L. Rutkowska –Sak, J. Jaworski, B. Wojciechowska. Reumatologia, 2007; 45/6.

  20. Leflunomid w terapii chorych na reumatoidalne zapalenie stawów – wstępna obserwacja efektu terapeutycznego i objawów niepożądanych.

    Maria Rell-Bakalarska, Janusz Jaworski, Lidia Rutkowska-Sak, Małgorzata Wieczorek, Małgorzata Kwiatkowska, Ewa Klimczak, Bożena Kowalczuk, Krzysztof Wojciech. Rell RU 2006; 44, 1: 19-25.

  21. „Przypadek chorego na reumatoidalne zapalenie stawów z pylicą płuc, mnogimi guzkami w płucach i amyloidozą. Kiedy można rozpoznać zespół Caplana?"

    Ewa Matyska-Piekarska, Janusz Jaworski, Jacek Pazdur, Jan K .Łącki. Reumatologia, 2006; 44, 5:285-290.

  22. Do cytokines modulate density of integrins on erytroblasts surface in anemia of chronic disease accompanying Rheumatoid Arthrtis?

    J. Jaworski, W. Maslinski, J. Pazdur, P. Sliwińska-Stanczyk, E. Kamińska-Tchorzewska, L. Jung, J.K. Lacki. Abstrakt EULAR 2006 in Amsterdam.

  23. Decreased expression of integrins on the haematopoetic cells of patients with rheumatoid arthritis.

    J. Jaworski, J.Pazdur, P. Maldyk, E. Kaminska-Tchorzewska. Abstrakt EULAR 2003 Lisbona.

  24. Występowanie rzęsistka policzkowego Trichomonas tenax w jamie ustnej pacjentów z reumatoidalnym zapaleniem stawów.

    B. Grytner-Ziencina, J. Jaworski, D. Cielecka, A. Gierczyk, M. Turkowicz. Reumatologia, 2003.

  25. Ocena wskazań do leczenia i zagrożeń wynikających z zastosowania cyklosporyny w reumatoidalnym zapaleniu stawów.

    E. Kubasiewicz, P. Śliwińska-Stańczyk, I. Morawska, E. Kamińska –Tchórzewska, J. Jaworski, J. Pazdur. Reumatologia, 1999, T37, 4.

  26. Zespół toczniopodobny u osoby z hiperprolaktynemią.

    J. Jaworski, J. Pazdur. Reumatologia, 1999.